Chromocell Therapeutics (CHRO) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Chromocell Therapeutics in October 2026.
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.
About This Stock
Chromocell Therapeutics Corp
CHRO
Current Price
$2.20
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
CHRO
Market Cap
$8.17M
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
Chromocell is generating reasonable cash flow, but its book value per share is quite low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CHRO
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: 5 August 2025
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.